Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wang, Jiaan-Der
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial	Recruiting	3	150	Europe, Canada, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor	11/28	11/28
PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors	Recruiting	2	12	Europe, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia B with Inhibitor, Hemophilia B	09/25	10/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B	Recruiting	2	120	Europe, Canada, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia A, Hemophilia B	03/26	06/26
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention	Recruiting	N/A	200	Europe, Canada, US, RoW	No Intervention	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia A, Hemophilia B	11/24	11/24